In the effective treatment group, the expression of inflammation, cytokines, and Toll-receptor-related genes (such as FOS, CCL4, and NR4A2) increased in the CD8+ T cells in tumor tissues after treatment. The gene discussed is NR4A2; the disease is neoplasm.